Overview

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This trial is an open-lable , multi-center, Phase 1/Phase 2 study that will evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and and immunogenicity of IMM01 combined with Azacitidine in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd

Collaborator:

Institute of Hematology & Blood Diseases Hospital

Treatments:

Azacitidine